Physician profile
John D Mosier
NPI 1982665287
$729.84
in general payments reported to CMS, 2019-2025
17 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11.38 · 2021: $167 · 2022: $521 · 2023: $30.65.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $30.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $30.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $117.17 | 2019-2022 | |
| Lilly USA, LLC | $78.39 | 2022 | |
| Pfizer INC. | $74.77 | 2021-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $68.44 | 2021-2022 | |
| Amgen INC. | $66.16 | 2021-2022 | |
| Abbvie INC. | $54.42 | 2021-2022 | |
| Astrazeneca Pharmaceuticals Lp | $49.11 | 2022 | |
| Medtronic, INC. | $46.54 | 2022 | |
| Merck Sharp & Dohme LLC | $31.65 | 2022 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $28.65 | 2022 | |
| Amarin Pharma, INC. | $23.51 | 2021 | |
| Sumitomo Pharma America, INC. | $17.79 | 2023 | Gemtesa |
| Sunovion Pharmaceuticals INC. | $17.26 | 2021 | |
| Acadia Pharmaceuticals INC | $16.70 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $15.52 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $11.99 | 2021 | |
| Edwards Lifesciences Corporation | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mosier listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.